Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials

UCLA's Jonsson Comprehensive Cancer Center

UCLA's Jonsson Comprehensive Cancer Center
JCCC: A Comprehensive Cancer Center
JCCC Member Directory
Calendar
Contact Us
Map and Directions to JCCC
Social Media
Connect via Mobile
Privacy Practices
 
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Joel Randolph (Randy) Hecht, M.D.
Joel Randolph (Randy) Hecht, M.D.

Specialty:

Cancer/Medical Oncology
Gastroenterology/Digestive Diseases

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Professor of Clinical Medicine, Department of Medicine, Hematology/Oncology, Gastrointestinal Oncology
Director, UCLA Gastrointestinal Oncology Program
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Medical Oncology, UCLA School of Medicine, 1995 - 1997
Gastroenterology, UCLA School of Medicine, 1988 - 1991
Residency:
Internal Medicine, Northwestern University Medical School, 1985 - 1987
Internship:
Internal Medicine, Northwestern University Medical School, 1984 - 1985
Medical Degree:
M.D., Eastern Virginia Medical School, 1984

Certification(s):

Medical Board Certification(s):
Medical Oncology, American Board of Internal Medicine, 1998
Gastroenterology, American Board of Internal Medicine, 1991
Internal Medicine, American Board of Internal Medicine, 1987

Contact Information:

Phone:
(310) 829-5471
Email:
jrhecht@mednet.ucla.edu

Practice Information:

Clinical Interest(s):
Cancers of the Digestive Tract

Scientific Interest(s):

Dr. Randy Hecht's research and clinical interests concern malignancies of the gastrointestinal tract. He participates in a range of activities and is particularly interested in translating laboratory findings into improved patient care.

Hecht's current research includes preclinical models of therapy with biological agents, novel imaging techniques, Phase I studies with gene therapy vectors and tyrosine kinase inhibitors and leading large clinical trials evaluating inhibitors of angiogenesis and the epidermal growth factor receptor.

Selected Cancer-Related Publications:

Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007 Sep; 110(5):980-8.

Ajani JA, Hecht JR, Ho L, et al. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006; 106(9):1908-16.

Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005; 23(16): 3697-705.

Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003; 21(5): 807-14.

Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003; 9(2): 555-61.

In the News: